July 2012
The essential resource for your practice
Volume XXI, Number 7

USPSTF Transparency and Accountability Act of 2012

The AUA co-authored a bipartisan bill, the USPSTF Transparency and Accountability Act, (H.R. 5998) which was introduced in the U.S. House of Representatives on Thursday, June 21, by Representatives Marsha Blackburn (R-TN) and John Barrow (D-GA).

Table of Contents


Coding Corner:

Will Modifier PD affect your Practice?

AUA, AACU & LUGPA Release Joint Response to Supreme Court Decision on Affordable Care Act

In response to the U.S. Supreme Court ruling to uphold the Patient Protection and Affordable Care Act (PPACA), representatives of the American Association of Clinical Urologists (AACU), the AUA and the Large Urology Group Practice Association (LUGPA), leading advocates for the specialty of urology, issued the following joint statement expressing their concern over the Supreme Court's decision:
“While we strongly advocate the provision of care for the millions of uninsured Americans who will benefit from the legislation, we are concerned that there are key aspects to this law that will, ultimately, hurt this nation’s ability to provide widespread care for its citizens.

AUA Guideline Q&A

AUA Guideline: Management of the Clinical T1 Renal Mass
By J. Stuart Wolf, Jr., MD and Steven C. Campbell, MD, PhD

Why is ablation not advocated for a healthy patient with a T1a renal mass? 

For index patient 1 (healthy, clinical T1a) surgical excision is a standard, preferably with partial nephrectomy (PN), while thermal ablation (TA) is only an option. For healthy patients there are a number of concerns about TA, most importantly an increased incidence of local recurrence, observed despite TA being used to treat smaller tumors and having shorter follow-up. Radiographic parameters for success are questioned, with some studies showing biopsy proven tumor recurrence despite loss of contrast enhancement. Additionally, surgical salvage is difficult due to fibrosis associated with the prior ablation.  

Aetna Will Require Dual Certification/Accreditation for In-office Surgical Pathology Labs

Starting January 1, 2013, Aetna will require that practices offering in-office surgical pathology testing be certified with Clinical Laboratory Improvement Amendments (CLIA), as well as one of the following accrediting entities:

  • College of American Pathologists (CAP); 
  • American Osteopathic Association/HFAP; or
  • The Joint Commission. 

If the additional accreditation is not obtained, practices will not be reimbursed for surgical pathology services billed in the Current Procedural Terminology (CPT) code range 88300-88314 and 88342. If these credentials are not obtained by January 1, 2013, laboratory services must be provided by Aetna in-network labs that include preferred laboratories Quest Diagnostics and AmeriPath.